Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Glucocorticoids in cancer therapy


Glucocorticoids are often included with other agents in cancer treatment although the mode of action is not clear. They are useful in the primary combination chemotherapy of both acute and chronic lymphocytic leukaemias, Hodgkins' and non-Hodgkin's lymphomas, multiple myeloma and breast cancer. Other uses for glucocorticoids in cancer patients include an anti-inflammatory action for the oedema of cranial and spinal metastases, a weak antihypercalcaemic effect and the ability to suppress tumour-related fever.

This is a preview of subscription content, log in to check access.


  1. 1.

    Udkow G. Steroid effects on leococyte counts. Drug Ther 1978; 8: 172–7.

  2. 2.

    Peters WP, Holland JF, Senn H et al. Corticosteroid administration and localised leucocyte mobilization in man. N Engl J Med 1972; 282: 342–5.

  3. 3.

    Weinberger C, Hollenberg SM, Rosenfield MG et al. Domain structure of human glucocorticoid receptor and its relationship to the v-erb-a oncogene product. Nature 1985; 318: 670–2.

  4. 4.

    Henderson ES. Treatment of acute leukaemia. Seminarsin Haematology 1969; 6: 271.

  5. 5.

    Thompson EB, Smith JR, Bourgeois S et al. Glucocorticoid receptors in human leukaemias and related diseases. Klin Wochenschr 1985; 63: 689–98.

  6. 6.

    Yarbro GS, Lippman ME, Johnson GE et al. Glucocorticoid receptors in subpopulations of childhood acute lymphoblastic leukaemia. Cancer Res 1977; 37: 2688–95.

  7. 7.

    Riehm H, Freikert H-H, Schrappe M et al. Treatment results of five ALL-BFM studies since 1970: implications of risk factors for prognosis. Haematol Blood Trans 1987; 30: 139–46.

  8. 8.

    Jones B, Shuster JJ, Holland JF. Lower incidence of meningeal leukaemia when dexamethasone is substituted for prednisone in the treatment of acute lymphocytic leukaemia. Proc Am Assoc Clin Oncol 1984; 3: 191.

  9. 9.

    Balis FM, Lester CM, Chrousos GP et al. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to prevention of meningeal leukaemia. J Clin Oncol 1987; 5: 202–7.

  10. 10.

    Gottlieb AJ, Weinberg V, Ellison RR et al. Efficacy of daunorubicin in the therapy of adult lymphocytic leukaemia: a prospective randomised trial by Cancer and Leukaemia Group B (CALGB). Blood 1984; 64: 267.

  11. 11.

    Galton DAG, Wiltshaw E, Szur L et al. The use of chlorambucil and steroids in the treatment of chronic lymphocytic leukaemia. Br J Haematol 1961; 7: 73.

  12. 12.

    Ezdinli EZ, Loeb V, Dorfman R et al. Corticosteroid therapy for lymphomas and chronic lymphocytic leukaemia. Cancer 1969; 23: 900.

  13. 13.

    Sawitzy A, Rai KR, Glidewell O et al. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukaemia. Blood 1977; 50: 1049.

  14. 14.

    French Cooperative Group on Chronic Lymphocytic leukaemia. Effectiveness of “CHOP” regimen in advanced untreated chronic lymphocytic leukaemia. Lancet 1986; i: 1346.

  15. 15.

    Todd M, Cadman E, Spiro P et al. A follow-up of a randomised study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma. J Clin Oncol 1984; 2: 986–93.

  16. 16.

    Gaynor ER, Rainey M, Dandy M et al. Treatment of diffuse histiocytic lymphoma (DHL) with COMLA: a 10 year experience in a single institution. J Clin Oncol 1985; 3: 1188–95.

  17. 17.

    Portlock CS, Rosenberg SA, Glatsetin E et al. Treatment of advanced non-Hodgkin's lymphomas with favourable histologies: preliminary results of a prospective trial. Blood 1976; 47: 747.

  18. 18.

    Lister TA, Cullen MH, Beard MEJ. Comparison of combined and single agent chemotherapy in non-Hodgkin lymphoma of favourable histological type. B Med J 1978; 1: 533.

  19. 19.

    Peterson BA, Frizzera G, Anderson JR et al. Response of low grade lymphomas to cyclophosphamide (CTX) or cyclophosphamide, adriamycin, vincristine, prednisolone and bleomycin (CAVPB). Proc ASCO 1985; 4: C-822.

  20. 20.

    British National Lymphoma Investigation. Value of prednisolone in stage IV Hodgkin's disease. Br Med J 1975; 3: 413.

  21. 21.

    Salmon SE, Shadduck RK, Schilling A. Intermittent high-dose prednisone therapy for multiple myeloma. Cancer Chemother Rep 1967; 51: 179.

  22. 22.

    Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Annals Internal Medicine 1986; 105: 8–11.

  23. 23.

    Dalton WS, Durie BGM, Alberts DS et al. Characterization of a new drug-resistant human myeloma cell line which expresses p-glycoprotein. Cancer Res 1986; 45: 5125–30.

  24. 24.

    Barlogie B, Smith L, Alexian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353–6.

  25. 25.

    Minton MJ, Knight RK, Rubens RD, Hayward JL. Corticosteroids for elderly patients with breast cancer. Cancer 1981; 48: 883–7.

  26. 26.

    Rees LH, Lowry PJ. Adrenocorticotrophin and lipotrophin. In: Gray CH and James VHT, eds. Hormones in blood. 3rd ed. London: Academic Press, 1979: 130–72.

  27. 27.

    Whittliff J, Savlov G. Biochemical basis for the selection of hormonal manipulation in the patient with breast cancer. Int J Radiat Oncol Phys 1978; 4: 463–7.

  28. 28.

    Lippman ME, Osborne CK, Knazek R et al.In vitro model systems for the study of hormone-dependent human breast cancer. New Engl J Med 1977, 296: 154–9.

  29. 29.

    Blackburn AM, Wang DY, Bulbrook RD et al. Effect of prednisolone on hormone profiles during primary endocrine treatment of advanced breast cancer. Cancer Treat Rep 1984; 68: 1447–53.

  30. 30.

    Nissen-Meyer R, Sanner T. The excretion of oestrone, prenanediol and pregnanetriol in breast cancer patients II. Effect of ovariectomy, ovarian ablation and corticosteroids. Acta Endocrinol 1963; 44: 334–45.

  31. 31.

    Moore JW, Clark GMG, Bulbrook RD et al. Serum concentrations of total and non-protein bound oestradiol in patients with breast cancer and normal controls. Int J Cancer 1982; 29: 17–21.

  32. 32.

    Wang DY, Rubens RD, Clark GMG et al. Effects of prednisolone on sex hormone binding globulin during primary treatment of advanced breast cancer. Breast Cancer Res Treat 1988; 11: 67.

  33. 33.

    Stewart JF, Rubens RD, King RJB et al. Contribution of prednisolone to the primary endocrine treatment of advanced breast cancer. Eur J Cancer Clin Oncol 1982; 18: 1307–14.

  34. 34.

    Rubens RD, Tinson CJ, Coleman RE et al. Prednisolone improves the response to primary endocrine treatment for advanced breast cancer. Br J Cancer 1988; 58: 626–30.

  35. 35.

    Stuart-Harris RC, Smith IE. Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev 1984; 11: 189–204.

  36. 36.

    Meakin JW, Allt WEC, Bealk FA et al. Ovarian irradiation and prednisolone therapy following surgery and radiotherapy for carcinoma of the breast. Can Med Assoc J 1979; 120: 1221.

  37. 37.

    Ludwig Breast Cancer Study Group. A randomised trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Research 1985; 45: 4454–9.

  38. 38.

    Tormey DC, Gelman R, Band P et al. Comparison of single to alternating combination therapy in metastatic breast cancer. Proc Am Assoc Cancer Res 1980; 21: 171.

  39. 39.

    Reulen HJ, Tsuyumu M, Tack A. Clearance of oedema fluid into CSF: a mechanism for resolution of vasogenic brain oedema. J Neurosurg 1978; 48: 754–64.

  40. 40.

    Weissman DE. Glucocorticoid treatment for brain metastases and epidural spinal cord compression: a review. J Clin Oncol 1988; 6: 543–51.

  41. 41.

    Schwartz ML, Tator CH, Hoffman HJ. The uptake of hydrocortisone in mouse brain and ependymoblastoma. J Neurosurg 1972; 36: 178–83.

  42. 42.

    Posner JB. Diagnosis and treatment of metastases to the brain. Clin Bull 1974; 4: 47–57.

  43. 43.

    Matsuoka S, Arakaki Y, Numaguchi K et al. The effect of dexamethasone on electroencephalograms in patients with tumours. With special reference to topographic computer display of delta activity. J Neurosurg 1978; 48: 601–8.

  44. 44.

    Marty R, Cain ML. Effects of corticosteroids (dexamethasone) administration on the brain scan. Radiology 1973; 107: 117–21.

  45. 45.

    Hatam A, Bergstrom M, Yu Z-Y et al. Effect of dexamethasone treatment on volume and contrast enhancement of intracranial neoplasms. J Comput Assist Tomogr 1983; 7: 295–300.

  46. 46.

    French LA, Galicich JH. The use of steroids for control of cerbral oedema. Clin Neurosurg 1964; 10: 212–23.

  47. 47.

    Renaudin J, Fewer D, Wilson CB et al. Dose-dependency of Decadron in patients with partially excised brain tumours. J Neurosurg 1973; 39: 302–5.

  48. 48.

    Cairncross JG, Kim JH, Posner JB. Radiation therapy for brain metastases. Ann Neurol 1980; 7: 529–41.

  49. 49.

    Ikeda H, Ushio Y, Hayakawa T et al. Oedema and circulatory disturbances in the spinal cord compressed by epidural neoplasms in rabbits. J Neutrosurg 1980; 52: 203–9.

  50. 50.

    Greenberg HS, Kim J-H, Posner JB. Epidural spinal cord compression from metastatic tumour. Results with a new treatment protocol. Ann. Neurol 1980; 47: 380–90.

  51. 51.

    Rubin P. Extradural spinal cord compression by tumour. Radiology 1969; 93: 1243–60.

  52. 52.

    Percival RC, Yates AJP, Gray RES et al. Role of glucocorticoids in management of malignant hypercalcaemia. Br Med J 1984; 289: 287.

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Coleman, R.E. Glucocorticoids in cancer therapy. Biotherapy 4, 37–44 (1992). https://doi.org/10.1007/BF02171708

Download citation

Key words

  • cancer chemotherapy
  • glucocorticoids
  • prednisolone